Skip to main content

Table 2 Clinical and economic outcomes between patients with a negative CDI test diagnosed via EIA or PCR assay

From: Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile

Outcome EIA (n = 141) PCR (n = 140) P value
No. of tests sent per patient 1.82 ± 1.35 1.41 ± 0.86 0.007
Turnaround time, hours 32.5 (4.3–91.7) 7.2 (2.4–16.9) < 0.001
Empiric antibiotic therapy prior to negative result 27 (19.1) 9 (6.4) 0.002
Time to antibiotic discontinuation, days 6 (0–89) 1 (0–14) 0.002
Antibiotic therapy after negative result 26 (18.4) 8 (5.7) 0.002
Duration of therapy after negative result, days 4 (0–88) 1 (0–14) 0.029
Contact isolation 11 (7.8) 24 (17.1) 0.018
Duration of contact isolation, days 2 (1–24) 1 (0–13) 0.008
Length of stay, days 13.5 ± 14.1 14.8 ± 11 0.378
Hospital costs 20,170.21 ± 21,160.43 22,167.86 ± 16,523.10 0.378
Medication costs 546.60 ± 790.39 188.96 ± 179.14 0.191
CDI assay costs 8.33 (8.33–33.32) 42.86 (42.86–171.44) < 0.0001
Total costs 20,290.00 ± 21,267.75 22,240.31 ± 16,535.50 0.391
  1. Data presented as mean ± SD, median (min–max), or n (%)
  2. aCosts presented in 2016 U.S. $